Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2019
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Enanta Pharma (ENTA) Misses Q4 EPS by 9c, Revenues Miss
November 21, 2019 4:01 PM ESTEnanta Pharma (NASDAQ: ENTA) reported Q4 EPS of $0.44, $0.09 worse than the analyst estimate of $0.53. Revenue for the quarter came in at $51.3 million versus the consensus estimate of $55.94 million.
Initiation of RSVP, a Phase 2b study of EDP-938 in adult outpatients with RSVEDP-297 selected as follow-on FXR agonist with differentiated preclinical profileRoyalty revenue for the quarter was $51.3 millionCash and marketable securities totaled approximately $400 million at September 30, 2019During 2019, we successfully... More
